

# RESPONSIBLE AND SUSTAINABLE UK EQUITY FUND

## COMMENTARY FOR QUARTER TO END SEPTEMBER 2021

### PERFORMANCE

	3 Months	6 Months	1 Year	3 Years	5 Years	10 Years
Fund Performance (B Class)	3.99%	8.78%	27.39%	18.33%	36.10%	147.62%
FTSE AllShare TR GBP	2.23%	7.95%	27.90%	9.53%	29.81%	119.18%
IA UK All Companies	2.70%	8.43%	32.11%	15.21%	38.35%	140.90%
Sector Quartile	1	2	3	2	2	2

Source: Morningstar. Figures compared on a Bid to Bid basis with Net Income Reinvested.

### REVIEW

The UK markets performed well in the quarter largely due to the continuing successful vaccine rollout and move to step four of the government's coronavirus easing plan which has led to improved economic recovery whilst the US markets also performed well. President Biden continued with attempts to implement his policy agenda. The Federal Reserve is increasingly expected to raise interest rates in 2022 and reduce its asset purchase programme.

The prime minister announced a move to step four of the government's coronavirus easing plan which saw the end of the work from home guidance, enforced wearing of face coverings and social distancing rules. The government broke a manifesto pledge with their plan to raise National Insurance rates to tackle NHS waiting lists and social care reform. The Bank of England unanimously voted to hold interest rates at 0.1% and by a 7-2 margin to continue the level of quantitative easing although concerns around higher inflation were signalled. The UK indices were in positive territory in the quarter with the FTSE 250 performing relatively better than the FTSE100 and FTSE Small Cap.

Elsewhere, the oil price was strong in the period, due to strong world economic growth and declining inventories. The quarter saw the vaccine rollout gather pace in Europe after a slow start. Despite increasing forecasts for Eurozone growth and inflation, the European Central Bank announced that it would not overreact to transitory supply shocks which are driving inflation higher.

### PERFORMANCE & ACTIVITY

Fund outperformance was aided by overweight positions in Electrical & Electronics Equipment and Pharmaceuticals & Biotechnology and underweight positions in Personal Care, Drug and Grocery stores. The zero exposure to Mining was another tailwind. Overweight positions in Medical Equipment & Services and Non-life Insurance and a zero exposure in Oil, Gas & Coal impacted performance. At a stock level, Porvair (Industrials), Spectris (Industrials) and Dechra (Pharmaceuticals) were amongst the biggest contributors to performance whilst detractors included Smith & Nephew (Medical Technology), Sabre (Insurance), NCC (Technology) and National Express (industrials).

Fund activity included topping up in Ashtead, Spectris, Johnson Service Group, Keller, National Express, Oxford Instruments, Porvair, Prudential, Close Brothers, Lloyds Banking Group, Taylor Wimpey, Smith & Nephew, GlaxoSmithKline, AstraZeneca, Relx, WH Smith, Bioventix, Sage, Victrex, NCC, James Fisher & Sons, IP Group, Sabre Insurance, Phoenix and Clinigen. We took part in the IPO of Microlise, a software company focusing on transport management. We participated in share placings for Hotel Chocolat, with the proceeds being used to fund capital investment to increase long term sales capacity.



## OUTLOOK

Mistrust still exists between the UK and EU, and the Northern Ireland protocol is likely to see increasing tensions between both sides. A structural shortage of heavy goods vehicles drivers has led to disruption in various industries and this disruption is likely to continue. Record wholesale gas and electricity prices have seen several energy retailers collapse and more could follow which could lead to a rise in the cost of living and have negative implications on consumer spending. European economic activity is likely to be strong as the vaccine rollout programme improves following a slow start although global supply chain bottlenecks could have a dampening effect. President Biden will continue in his attempts to pass his policy agenda through Congress although this will be tough given the wafer thin majorities held by the Democrats in both houses of Congress. Central bankers around the world will continue in their quest to ascertain whether the current inflationary environment is transitory or permanent and this will have implications for the future path of interest rates and support programmes.

While, as ever, some political and economic risks lie ahead, we remain focused on finding new opportunities in companies that meet our strict criteria of strong earnings growth, high margins and strong cash flows. The Fund's focused and disciplined investment strategy has delivered material outperformance over the FTSE All Share over year to date, 3, 5 and 10 years.

To obtain further information please speak to your normal EdenTree representative, visit [www.edentreeim.com](http://www.edentreeim.com) or call our support team on **0800 011 3821**

This document has been prepared by EdenTree Investment Management Limited for Financial Advisors, other intermediaries and other investment professionals only. It is not suitable for private individuals. This document has been produced for information purposes only and as such the views contained herein are not to be taken as advice or recommendation to buy or sell any investment or interest thereto.

A full explanation of the characteristics of the investments is given in the Key Investor Information Document (KIID). Any forecast, figures, opinions statements of financial market trends or investment techniques and strategies expressed are unless otherwise stated, EdenTree Investment Management's own at the date of this document. They are considered to be reliable at the time of writing, may not necessarily be all-inclusive and are not guaranteed as to accuracy. There is no guarantee that any forecast made will come to pass. Please note that the value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations, you may not get back the amount originally invested. Past performance is not necessarily a guide to future returns.

EdenTree Investment Management Limited (EdenTree) Reg. No. 2519319. Registered in England at Benefact House, 2000, Pioneer Avenue, Gloucester Business Park, Brockworth, Gloucester, GL3 4AW, United Kingdom.

EdenTree is authorised and regulated by the Financial Conduct Authority and is a member of the Investment Association. Firm Reference Number 527473.